Technical Analysis for MGX - Metagenomi, Inc.

Grade Last Price % Change Price Change
F 1.65 -2.37% -0.04
MGX closed down 2.37 percent on Wednesday, November 20, 2024, on 1.93 times normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. The bears made the stock sink to a new 52-week low. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A Down Down

Date Alert Name Type % Chg
New 52 Week Closing Low Bearish 0.00%
Stochastic Buy Signal Bullish 0.00%
Calm After Storm Range Contraction 0.00%
NR7 Range Contraction 0.00%
Lower Bollinger Band Walk Weakness 0.00%
New 52 Week Low Weakness 0.00%
Wide Bands Range Expansion 0.00%
Below Lower BB Weakness 0.00%
Down 3 Days in a Row Weakness 0.00%
Down 4 Days in a Row Weakness 0.00%

   Recent Intraday Alerts

Alert Time
Possible NR7 about 17 hours ago
3x Volume Pace about 21 hours ago
2x Volume Pace about 22 hours ago
1.5x Volume Pace about 22 hours ago
Down 3% about 22 hours ago

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Metagenomi, Inc. Description

Metagenomi, Inc., a gene editing biotechnology company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Molecular Biology Genetic Engineering CRISPR Genome Editing Biological Engineering Gene Editing Human Cancer

Is MGX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 12.74
52 Week Low 1.62
Average Volume 354,752
200-Day Moving Average 0.00
50-Day Moving Average 2.10
20-Day Moving Average 1.99
10-Day Moving Average 1.93
Average True Range 0.17
RSI (14) 31.03
ADX 20.92
+DI 14.91
-DI 23.16
Chandelier Exit (Long, 3 ATRs) 1.82
Chandelier Exit (Short, 3 ATRs) 2.13
Upper Bollinger Bands 2.29
Lower Bollinger Band 1.68
Percent B (%b) -0.05
BandWidth 30.69
MACD Line -0.10
MACD Signal Line -0.07
MACD Histogram -0.0338
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.79
Resistance 3 (R3) 1.80 1.76 1.77
Resistance 2 (R2) 1.76 1.72 1.75 1.76
Resistance 1 (R1) 1.70 1.70 1.68 1.70 1.75
Pivot Point 1.66 1.66 1.65 1.66 1.66
Support 1 (S1) 1.61 1.63 1.59 1.60 1.55
Support 2 (S2) 1.57 1.60 1.56 1.54
Support 3 (S3) 1.51 1.57 1.53
Support 4 (S4) 1.51